World Courant
World-leading dementia scientists talk about the controversies surrounding new Alzheimer’s medicines.
Dementia impacts 55 million folks worldwide, and its most typical kind, Alzheimer’s, accounts for about 70 p.c of all circumstances.
On the Alzheimer’s Affiliation Worldwide Convention, the biggest congress advocating dementia science, held in Amsterdam this month, a pharmaceutical firm disclosed particulars of its trials of a brand new drug: donanemab.
The American firm, Eli Lilly, expects the USA Meals and Drug Administration (FDA) to determine by the tip of 2023 whether or not to approve what it’s calling a “breakthrough” drug.
However is that this remedy one of the best ways ahead? Or does it simply provide money stream for the pharmaceutical business?
Main dementia scientists Edo Richard and Craig Ritchie speak to Al Jazeera.
Edo Richard and Craig Ritchie: Are Alzheimer’s medication false hope? | Well being
Africa Area Information ,Subsequent Large Factor in Public Knowledg
